Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Axel, Hoos"'
Autor:
Junping Jing, Laura Bover, C Ian Mockridge, Kerry L Cox, Mark S Cragg, Tatyana Inzhelevskaya, Chris A Penfold, Vikki English, Jane E Willoughby, Hong Shi, Peter J Morley, Heather Jackson, Roopa Srinivasan, Tom Murray, Axel Hoos, Paul Bojczuk, James Smothers, Niranjan Yanamandra, Lang Dou, Sabyasachi Bhattacharya, Laura Seestaller-Wehr, David Kilian, Kui S Voo, Mel John, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Sara J Brett, Christopher Hopson, Elaine Paul, Stephen L Martin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background OX40 has been widely studied as a target for immunotherapy with agonist antibodies taken forward into clinical trials for cancer where they are yet to show substantial efficacy. Here, we investigated potential mechanisms of action of anti-
Externí odkaz:
https://doaj.org/article/1d4a1e220c0f453894379600a08cb4a4
Autor:
Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.Methods GSK3
Externí odkaz:
https://doaj.org/article/cede222f65c649b89ade485245fc9ae7
Autor:
Agathe Dubuisson, Jean‐Eudes Fahrner, Anne‐Gaëlle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Séverine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camélia Radulescu, Sophie Ferlicot, David J Figueroa, Sapna Yadavilli, Jeremy D Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, François Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice André, Cédric Lebacle, Hervé Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean‐Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurélien Marabelle, Mélodie Bonvalet, Laurence Zitvogel
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an
Externí odkaz:
https://doaj.org/article/67054ca5ed634665a330aa95af51b5fb
Autor:
Jeffrey Weber, Hassane Zarour, David Carbone, Marcus Butler, Roma Patel, Melissa Johnson, Adrian Sacher, Edward Garon, Arindam Dhar, Cristina Messina, Kristin Blouch, Axel Hoos, Anne-Marie Martin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/53ad820e499e4b9d86e1c453a86a2cd6
Autor:
F. Stephen Hodi, Rachel Humphrey, Geoffrey Nichol, Oliver Bohnsack, Michael Binder, Michele Maio, Celeste Lebbé, Omid Hamid, Jeffrey S. Weber, Steven O'Day, Axel Hoos, Jedd D. Wolchok
Purpose: Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes. Resulting clinical response patterns extend beyond those of cytotoxic agents and can manifest after an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4478970fcd76651243c3b3a282a13b
https://doi.org/10.1158/1078-0432.c.6517623.v1
https://doi.org/10.1158/1078-0432.c.6517623.v1
Autor:
Patrick Hwu, Niranjan Yanamandra, Elaine M. Paul, Roopa Srinivasan, James Smothers, Axel Hoos, Michael A. Davies, Hussein A. Tawbi, Gregory Lizee, Jian Wang, Sara Elizabeth Leahey, Rina M. Mbofung, Kui S. Voo, Heather L. Jackson, Yuan Chen, Jodi A. McKenzie, Brenda Melendez, Chunyu Xu, Leila J. Williams, Weiyi Peng
The cytokine changes in mice receiving PI3K inhibition in combination with anti-OX40 treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f6039acfa1d8709a210d4ff0939de3
https://doi.org/10.1158/1078-0432.22472204.v1
https://doi.org/10.1158/1078-0432.22472204.v1
Autor:
Axel Hoos, James Smothers, Shu Zhang, Junping Jing, Lyuben Tsvetkov, Chris Hopson, Shu-Yun Zhang, Laura Seestaller-Wehr, Jingsong Yang, Tianqian Zhang, Sapna Yadavilli, Hong Shi, Stephen Eastman, Patrick A. Mayes, Li Liu
Supplementary Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c132032d92e87d5e6b477ea82f956e1
https://doi.org/10.1158/1078-0432.22461912
https://doi.org/10.1158/1078-0432.22461912
Autor:
Axel Hoos, James Smothers, Shu Zhang, Junping Jing, Lyuben Tsvetkov, Chris Hopson, Shu-Yun Zhang, Laura Seestaller-Wehr, Jingsong Yang, Tianqian Zhang, Sapna Yadavilli, Hong Shi, Stephen Eastman, Patrick A. Mayes, Li Liu
Purpose: To assess the immunologic effects of dabrafenib and trametinib in vitro and to test whether trametinib potentiates or antagonizes the activity of immunomodulatory antibodies in vivo.Experimental Design: Immune effects of dabrafenib and trame
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::661aaed347926a54cf4ec666b3845e7f
https://doi.org/10.1158/1078-0432.c.6524868.v1
https://doi.org/10.1158/1078-0432.c.6524868.v1
Autor:
Patrick Hwu, Niranjan Yanamandra, Elaine M. Paul, Roopa Srinivasan, James Smothers, Axel Hoos, Michael A. Davies, Hussein A. Tawbi, Gregory Lizee, Jian Wang, Sara Elizabeth Leahey, Rina M. Mbofung, Kui S. Voo, Heather L. Jackson, Yuan Chen, Jodi A. McKenzie, Brenda Melendez, Chunyu Xu, Leila J. Williams, Weiyi Peng
Supplementary Figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fed6dfda111375a3bc5f8f7a1df7f23
https://doi.org/10.1158/1078-0432.22472201.v1
https://doi.org/10.1158/1078-0432.22472201.v1
Autor:
Patrick Hwu, Niranjan Yanamandra, Elaine M. Paul, Roopa Srinivasan, James Smothers, Axel Hoos, Michael A. Davies, Hussein A. Tawbi, Gregory Lizee, Jian Wang, Sara Elizabeth Leahey, Rina M. Mbofung, Kui S. Voo, Heather L. Jackson, Yuan Chen, Jodi A. McKenzie, Brenda Melendez, Chunyu Xu, Leila J. Williams, Weiyi Peng
Purpose:OX40 agonist–based combinations are emerging as a novel avenue to improve the effectiveness of cancer immunotherapy. To better guide its clinical development, we characterized the role of the OX40 pathway in tumor-reactive immune cells. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21ac271984f7d9259de1b307571c8647
https://doi.org/10.1158/1078-0432.c.6528155.v1
https://doi.org/10.1158/1078-0432.c.6528155.v1